uBiome Appoints Dr. Mahboobeh Mahdavinia, MD, PhD, Nasal Microbiome Researcher, to its Medical Advisory Board

Share Article

The leader in microbial genomics appoints allergist and immunologist to its board of medical advisors.

"I am excited to join the consulting board of uBiome and hope our cumulative efforts can help us find important clues and a breakthrough for this global issue.” - Dr. Mahdavinia, MD, PhD

uBiome, the leader in microbial genomics, announces the addition of Dr. Mahboobeh Mahdavinia, MD, PhD, Assistant Professor in the Department of Internal Medicine at Rush Medical College, to its Medical Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Mahdivinia will bring to uBiome expertise about the nasal microbiome and chronic rhinosinusitis. The appointment will help uBiome continue to advance the science of the microbiome and make it useful to people.

“Dr. Mahdivinia’s research on the nasal microbiome and its relation to asthma and chronic rhinosinusitis is important and groundbreaking,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “As a member of our scientific advisory board, Dr. Mahdavinia will be a fantastic resource to uBiome.”

Dr. Mahdavinia is an Assistant Professor in the Department of Internal Medicine at Rush Medical College in Chicago. She completed her residency at the University of Pittsburgh Medical Center and her fellowship at Northwestern Memorial Hospital, where she received an American Academy of Allergy Asthma & Immunology fellow-in-training Abstract Award. Dr. Mahdavinia’s specialty is allergy and immunology, and she has published several peer-reviewed articles about chronic rhinosinusitis and the nasal microbiome.

About joining uBiome's Medical Advisory Board, Dr. Mahdavinia said, “In the world of allergy and immunology, we have witnessed a dramatic rise in allergic diseases in past decades, which has created a global quest to find answers for. I believe studying the microbiome is a key to this answer, and have focused my research on the link between nasal microbiome and allergic inflammation. I am excited to join the consulting board of uBiome and hope our cumulative efforts can help us find important clues and a breakthrough for this global issue.”

In addition to Dr. Mahdavinia, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.

_____
About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.

uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

uBiome Public Relations
@uBiome
Follow >
Visit website